Kazia (NASDAQ: KZIA) updates ADS prospectus, flags new kaziatx.com site

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement under its Form F-1 registration statement to update the prospectus for an offering of 95,110 American Depositary Shares (ADSs), representing 47,555,000 ordinary shares. The supplement incorporates information from a Form 6-K dated August 31, 2026.

Kazia reports that on August 28, 2026 it launched a new website at www.kaziatx.com, and prior references to www.kaziatherapeutics.com in its SEC materials should be read to refer to the new URL. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $13.58 per ADS on August 28, 2026. The Form 6-K content is also incorporated by reference into Kazia’s Form F-3 registration statements (File Nos. 333-276091, 333-281937 and 333-294392).

Filing Explained

This August 31 Form 424B3 is an informational prospectus update: it attaches the company’s August 31 Form 6-K about a website change and discloses no new offering terms, sale, proceeds, issuance, or dilution for existing holders.

Key Figures

ADSs offered: 95,110 ADSs Ordinary shares represented: 47,555,000 ordinary shares Last reported ADS price: $13.58 per ADS +3 more

6 metrics

ADSs offered 95,110 ADSs Amount referenced in the updated prospectus

Ordinary shares represented 47,555,000 ordinary shares Ordinary shares represented by 95,110 ADSs

Last reported ADS price $13.58 per ADS Nasdaq Capital Market, August 28, 2026

Form F-3 file number 333-276091 Form F-3 registration statement incorporating this Form 6-K

Form F-3 file number 333-281937 Form F-3 registration statement incorporating this Form 6-K

Form F-3 file number 333-294392 Form F-3 registration statement incorporating this Form 6-K

Key Terms

American Depositary Shares, prospectus supplement, Form 6-K, foreign private issuer, +1 more

5 terms

American Depositary Shares financial

"95,110 American Depositary Shares representing 47,555,000 Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

prospectus supplement financial

"This prospectus supplement is being filed to update and supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Form 6-K regulatory

"with the information contained in our current report on Form 6-K"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

incorporates by reference regulatory

"The Company hereby incorporates by reference the information contained herein"

Offering Details

shelf

Offering

Offering Type shelf

FAQ

What does Kazia Therapeutics (KZIA) update in this prospectus supplement?

Kazia Therapeutics updates its Form F-1 prospectus to incorporate information from an August 31, 2026 Form 6-K and to reflect details related to an offering of 95,110 ADSs representing 47,555,000 ordinary shares.

How many securities are covered in the updated Kazia (KZIA) prospectus?

The updated prospectus covers 95,110 American Depositary Shares, which represent 47,555,000 ordinary shares of Kazia Therapeutics Limited.

What new website did Kazia Therapeutics (KZIA) launch in August 2026?

On August 28, 2026, Kazia Therapeutics launched a new website at www.kaziatx.com, and states that prior references to www.kaziatherapeutics.com in its SEC materials should now be read as referring to this new URL.

On which exchange are Kazia (KZIA) ADSs listed and what was the recent price?

Kazia’s American Depositary Shares are listed on the Nasdaq Capital Market under the symbol KZIA. On August 28, 2026, the last reported sale price of the ADSs was $13.58 per ADS.

Which Kazia Therapeutics (KZIA) registration statements incorporate this Form 6-K by reference?

Kazia states that the information in this Form 6-K is incorporated by reference into its registration statements on Form F-3, File Nos. 333-276091, 333-281937 and 333-294392.

Where does Kazia (KZIA) direct investors for risk factor information?

Kazia directs investors to the “Risk Factors” section beginning on page 9 of the prospectus and to “Item 3. Key Information–D. Risk Factors” in its most recent Form 20-F, as well as other recently filed reports and any applicable prospectus supplements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 07:33 AM Accepted by SEC EDGAR 08/31/2026 - 07:31 AM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-276774

PROSPECTUS SUPPLEMENT

(to Prospectus dated December 22, 2025)

95,110 American Depositary Shares representing

47,555,000

Ordinary Shares

Kazia Therapeutics Limited

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-276774), as amended, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on August 31, 2026 (the “August 31, 2026 Form 6-K”). Accordingly, we have attached the August 31, 2026 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On August 28, 2026, the last reported sale price of the ADSs on Nasdaq was $13.58 per ADS.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 31, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 28, 2026, Kazia Therapeutics Limited (the “Company”) launched a new website. The new website can be found at www.kaziatx.com.

Any prior references to the Company’s website, including references to www.kaziatherapeutics.com, in the Company’s filings with the Securities Exchange Commission (the “SEC”) should be read to refer to the new URL, www.kaziatx.com, as applicable.

The new website has been designed to provide investors, customers, and other stakeholders with enhanced access to information regarding the Company’s business, products, services, clinical trials, and corporate developments. We encourage investors, patients, business partners, researchers, and other stakeholders to review the information we post on our website, in addition to following our press releases and SEC filings.

Incorporation by Reference

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
Date: August 31, 2026	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer

2